DNA
APC | MSH6 | ARID1A | MYC | BRAF | NRAS | CDKN2A | PIK3CA | CTNNB1 | PMS2 | ERBB2 | ERBB3 |
PTEN | FBXW7 | RNF43 | GNAS | SMAD4 | KRAS | SOX9 | MLH1 | TCF7L2 | MSH2 | TP53 | POLE |
FUSION
NTRK1 Fusion | NTRK2 Fusion | NTRK3 Fusion | HER2/ERBB2 FISH | RET Fusion | PD-L1 IHC | Microsatellite Instability (MSI) |
Method: Next Generation Sequencing (NGS)
Sample Type: Tissue, Blood (Liquid Biopsy Tube)
Result Time: 20-25 Days
Sensitivity: 99%
Description: 26 Genes - 4 Fusions + 1 FISH + MSI + PD-L1 IHC
COLORECTAL PLUS PANEL
✓ Paraffin Block ✓ Liquid Biopsy
COLORECTAL PLUS PANEL
There are highly effective treatment options (IMMUNOTHERAPIES, EGFR-BRAF-KRASG12C INHIBITORS, ANTI-HER2 THERAPIES) that can be used in addition to conventional chemotherapies when planning colorectal cancer treatment. For example, when microsatellite instability is detected, responses up to 80% can be achieved with immunotherapies. Therefore, comprehensive genetic and microsatellite analyses are recommended to determine the treatment.